Intercepting Cancer When DNA Surveillance Fails
Get the full intelligence
Search transcripts, export clips, track mentions, and explore all topics from “Intercepting Cancer When DNA Surveillance Fails” inside PodZeus.
This episode of The BioReport explores the groundbreaking work of Newscom, a biotech company led by CEO Marina Udier, in developing off-the-shelf cancer vaccines to intercept cancer before it forms—particularly in high-risk individuals with Lynch syndrome. The discussion centers on microsatellite instability (MSI), a genetic condition caused by defective DNA mismatch repair that leads to an accumulation of mutations, including frame-shift peptides that serve as ideal targets for the immune system. Newscom’s lead candidate, NuStor9, is a viral vector-based vaccine containing 209 shared neoantigens derived from these mutations, designed to train the immune system to recognize and destroy precancerous cells. The company’s 'cancer interception' strategy shifts focus from treating established tumors to preventing cancer in genetically predisposed individuals, offering a paradigm shift from current standards like frequent colonoscopies and prophylactic surgeries. Early clinical data show strong, durable immune responses and promising clinical outcomes in both metastatic and Lynch syndrome settings, with the vaccine proving safe and effective as a monotherapy in pre-cancerous states and synergistic with PD-1 inhibitors in advanced disease. The episode also delves into the broader implications of this approach, including the critical gap in genetic testing for Lynch syndrome despite widespread MSI screening, and how the availability of a preventive therapy like NuStor9 could dramatically increase testing rates. Newscom has raised $140 million in funding, with plans to advance into late-stage development, supported by robust clinical data published in Nature Medicine. The company is actively exploring strategic partnerships with big pharma to scale global trials and prepare for market entry. With a platform that works across both off-the-shelf and personalized vaccine models, Newscom is positioning itself at the forefront of a new era in cancer prevention, where immunotherapy is used not just to treat, but to stop cancer before it starts.
Cancer interception using off-the-shelf vaccines like NuStor9 can prevent cancer in high-risk individuals with Lynch syndrome by training the immune system to target precancerous cells before tumors form.
Microsatellite instability (MSI) creates unique, shared neoantigens (frame-shift peptides) that are ideal targets for universal cancer vaccines because they are tumor-specific and absent in healthy tissues.
NuStor9 induces broad, durable CD8+ T-cell responses and has shown safety and efficacy in both metastatic and pre-cancerous settings, with clinical responses correlating to immune activation.
Combining NuStor9 with PD-1 inhibitors enhances anti-tumor effects by activating new T-cell responses while overcoming immune exhaustion, making it a powerful combination in advanced disease.
The biggest unmet need in Lynch syndrome is the lack of preventive therapy—current care relies on surveillance and surgery, but vaccines offer true biological prevention.
…and 3 more takeaways available in PodZeus
The Promise of Cancer Interception in Lynch Syndrome
“Instead of waiting for the disease at whichever stage to present with symptoms and treating it, we train the immune system to eliminate precancerous and early cancer cells as they emerge.”
Understanding Microsatellite Instability and DNA Repair Failure
Marina explains microsatellite instability (MSI) as a failure of the body’s DNA spellcheck system, leading to accumulation of mutations in repetitive DNA sequences. She details how defective mismatch repair genes cause these errors to go uncorrected, resulting in frame-shift peptides that are unique to tumor cells.
The Science Behind NuStor9: A Universal Off-the-Shelf Vaccine
“You really need to have a high payload with the goal to result in a high-quality T cell responses which are then going to translate into good clinical outcomes.”
From Detection to Prevention: The Cancer Interception Paradigm
“It could represent a game-changing shift from the life of waiting to get cancer to the life of actually being able to do something about it.”
Clinical Evidence, Safety, and Future Development
“We observed a complete absence of cancer or even advanced adenomas in the context of the trial that we ran.”
“Instead of waiting for the disease at whichever stage to present with symptoms and treating it, we train the immune system to eliminate precancerous and early cancer cells as they emerge.”
“It could represent a game-changing shift from the life of waiting to get cancer to the life of actually being able to do something about it.”
“We observed a complete absence of cancer or even advanced adenomas in the context of the trial that we ran.”
Host
Guest
Newscom
organization
NuStor9
product
Marina Udier
person
Microsatellite Instability
other
Lynch Syndrome
other
DNA Mismatch Repair
other
PD-1 Inhibitor
product
Pembrolizumab
product
Levine Media Group
organization
Jonah Levine
person
Targeting Psychosis in Alzheimer’s Disease
The Bio Report • 22m • 4/1/2026
Tuning, Rather than Blocking, Immunity in IBD
The Bio Report • 35m • 4/15/2026
Slowing Disability in MS
The Bio Report • 29m • 4/22/2026
An Off-the-Shelf Cell Therapy to Calm Cytokine Storms
The Bio Report • 28m • 4/29/2026
Addressing Treatment Gaps in Gout
The Bio Report • 36m • 5/6/2026
Get the full intelligence
Search transcripts, export clips, track mentions, and explore all topics from “Intercepting Cancer When DNA Surveillance Fails” inside PodZeus.
Start discovering podcast insights today
Start with a 7-day trial and explore a growing catalog of popular podcasts. No credit card required.
No credit card required • 7-day trial • Cancel anytime